search
Back to results

Comparison Between Oral Contraceptive Pills and Calcium Supplements in Treatment of Premenstrual Syndrome (PMS)

Primary Purpose

Premenstrual Syndrome

Status
Completed
Phase
Phase 3
Locations
Egypt
Study Type
Interventional
Intervention
Yasmin
Calver
Placebo 1
Placebo 2
Sponsored by
Beni-Suef University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Premenstrual Syndrome focused on measuring Premenstrual syndrome, Oral contraceptive pills, Calcium Supplements

Eligibility Criteria

18 Years - 40 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients diagnosed by prospective dairy to have PMS
  • Consenting to be included in the study
  • Age 18-40 years

Exclusion Criteria:

  • Medical disorders as hypertension or diabetes.

Sites / Locations

  • Beni-Suef University

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

Yasmin

Calver

Placebo

Arm Description

Yasmin is an oral contraceptive pill containing (Disperinone 3mg+Ethinylestradiol 0.3mg) will be administered once daily orally by the woman from day 2 of the cycle for 21 days each month for 3 months in addition to a daily placebo.

Calver is a calcium supplement drug containing (ca 1000mg+vit D400 I.U) given to the woman continuously for 3 months in addition to placebo for 21 days

A daily oral placebo will be given to the patients daily for 3 months in addition to a placebo similar to COC for 21 days

Outcomes

Primary Outcome Measures

Improvement of premenstrual symptoms.
Improvement of symptoms will be assessed by comparing the pre-treatment recorded DRSP with that recorded 3 months after starting treatment.

Secondary Outcome Measures

Full Information

First Posted
March 2, 2014
Last Updated
August 7, 2015
Sponsor
Beni-Suef University
search

1. Study Identification

Unique Protocol Identification Number
NCT02089620
Brief Title
Comparison Between Oral Contraceptive Pills and Calcium Supplements in Treatment of Premenstrual Syndrome
Acronym
PMS
Official Title
Calcium Supplements Versus Oral Contraceptive Pills Containing Drospirenone in Treating Mild to Moderate Premenstrual Syndrome: A Double Blind Randomized Placebo Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2015
Overall Recruitment Status
Completed
Study Start Date
May 2014 (undefined)
Primary Completion Date
June 2015 (Actual)
Study Completion Date
June 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beni-Suef University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Premenstrual syndrome represents a group of problems affecting most of women in reproductive age. These problems include emotional and physical symptoms. In this study the efficacy of oral contraceptive pills and calcium supplements in relieving these symptoms will be assessed .
Detailed Description
Premenstrual syndrome (PMS) is defined as the recurrence of psychological and physical symptoms in the luteal phase, which remit in the follicular phase of the menstrual cycle [1].PMS will be prospectively diagnosed using the Royal college of Obstetricians and Gynecologists (RCOG) recommended daily record of severity of problems (DRSP) . Women will be asked to fill the diary for 2 months, only women with 30% increase in the DRSP score in the week before menses in both months will be diagnosed as having PMS. Women with PMS will be invited to participate in the study.The invitation will include a clear full explanation of the study and patients will provide written consents. All patients consenting to participate will be included in the trial. Yasmin, Calver and Placebo will be enclosed in sequentially numbered similar bottles which will be numbered using a computer generated random table. Women will be asked to choose a sealed envelope, each envelope will contain the number allocated to the jar and special instructions on how to use the medication. Yasmin will be taken once daily for 21 days starting from the 2nd day of menstruation, Calver and placebo will be taken continuously. Neither the patients nor the physician will be aware of the drug used. Patients will be categorized in 3 groups: group1 who will receive Yasmin cyclically for 3 months (Yasmin, schering, cairo, Egypt) and daily oral placebo, group 2 who will receive Calver continuously for 3 months (Calver, Marcryl/Vertex, Cairo Egypt) and oral placebo for 21 days, group 3 who will receive a daily placebo and a placebo similar to COC for 21 days and will act as a control group.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Premenstrual Syndrome
Keywords
Premenstrual syndrome, Oral contraceptive pills, Calcium Supplements

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
210 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Yasmin
Arm Type
Active Comparator
Arm Description
Yasmin is an oral contraceptive pill containing (Disperinone 3mg+Ethinylestradiol 0.3mg) will be administered once daily orally by the woman from day 2 of the cycle for 21 days each month for 3 months in addition to a daily placebo.
Arm Title
Calver
Arm Type
Active Comparator
Arm Description
Calver is a calcium supplement drug containing (ca 1000mg+vit D400 I.U) given to the woman continuously for 3 months in addition to placebo for 21 days
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
A daily oral placebo will be given to the patients daily for 3 months in addition to a placebo similar to COC for 21 days
Intervention Type
Drug
Intervention Name(s)
Yasmin
Other Intervention Name(s)
OCP
Intervention Description
will be used every 21 days for three months by the patient
Intervention Type
Dietary Supplement
Intervention Name(s)
Calver
Other Intervention Name(s)
Calcium supplement
Intervention Description
Calver will be given daily for 3 months
Intervention Type
Drug
Intervention Name(s)
Placebo 1
Intervention Description
Patients will receive a daily placebo similar in size and structure to calvar.
Intervention Type
Drug
Intervention Name(s)
Placebo 2
Intervention Description
Women will receive an oral placebo similar to COC for 21 days starting from the 3rd day of menstruation
Primary Outcome Measure Information:
Title
Improvement of premenstrual symptoms.
Description
Improvement of symptoms will be assessed by comparing the pre-treatment recorded DRSP with that recorded 3 months after starting treatment.
Time Frame
3 months after starting treatment.

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients diagnosed by prospective dairy to have PMS Consenting to be included in the study Age 18-40 years Exclusion Criteria: Medical disorders as hypertension or diabetes.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nesreen A Shehata, Lecturer
Organizational Affiliation
Beni-Suef University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Abdelgany M Hassan, Lecturer
Organizational Affiliation
Cairo University
Official's Role
Study Chair
Facility Information:
Facility Name
Beni-Suef University
City
Beni-Suef
Country
Egypt

12. IPD Sharing Statement

Citations:
PubMed Identifier
16172836
Citation
Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Womens Ment Health. 2006 Jan;9(1):41-9. doi: 10.1007/s00737-005-0103-y. Epub 2005 Sep 20.
Results Reference
background
PubMed Identifier
11588078
Citation
Wyatt K, Dimmock P, Jones P, Obhrai M, O'Brien S. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ. 2001 Oct 6;323(7316):776-80. doi: 10.1136/bmj.323.7316.776.
Results Reference
background
PubMed Identifier
26808666
Citation
Shehata NAA. RETRACTED: Calcium versus oral contraceptive pills containing drospirenone for the treatment of mild to moderate premenstrual syndrome: a double blind randomized placebo controlled trial. Eur J Obstet Gynecol Reprod Biol. 2016 Mar;198:100-104. doi: 10.1016/j.ejogrb.2016.01.015. Epub 2016 Jan 13.
Results Reference
derived

Learn more about this trial

Comparison Between Oral Contraceptive Pills and Calcium Supplements in Treatment of Premenstrual Syndrome

We'll reach out to this number within 24 hrs